Cardiff Oncology financials
$1.17−2.50%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $593.0K | $683.0K | $488.0K | $386.0K | $359.0K | $366.0K |
| Gross profit | $593.0K | $683.0K | $488.0K | $386.0K | $359.0K | $366.0K |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$49.0M | -$48.7M | -$45.4M | -$39.9M | -$28.9M | -$19.1M |
| Net income | -$45.9M | -$45.5M | -$41.5M | -$38.7M | -$28.3M | -$22.6M |
| Net margin | −7736.3% | −6655.2% | −8496.9% | −10033.2% | −7887.2% | −6174.3% |
| Diluted EPS | $-0.69 | $-0.95 | $-0.93 | $-0.89 | $-0.73 | $-1.08 |
| EBITDA | -$48.6M | -$48.2M | -$45.0M | -$39.7M | -$28.4M | -$18.6M |
| Operating cash flow | -$37.9M | -$37.7M | -$30.9M | -$33.8M | -$23.0M | -$16.3M |
| Free cash flow | -$38.0M | -$37.8M | -$31.5M | -$34.8M | -$23.2M | -$16.5M |
| Diluted shares | 66.8M | 47.7M | 44.7M | 43.6M | 39.0M | 20.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $17.5M | $51.5M | $21.7M | $16.3M | $11.9M | $131.0M |
| Short-term investments | $40.8M | $40.3M | $53.2M | $88.9M | $128.9M | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $61.9M | $97.2M | $81.6M | $116.2M | $149.5M | $134.7M |
| Total liabilities | $16.5M | $14.2M | $11.9M | $9.8M | $9.1M | $6.6M |
| Shareholders' equity | $45.4M | $82.9M | $69.7M | $106.3M | $140.4M | $128.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology